SEARCH

SEARCH BY CITATION

References

  • 1
    Stafford RS, Monti V, Furberg CD, Ma J. Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension. 2006;48:213218.
  • 2
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SYST-EUR) trial investigators. Lancet. 1997;350:757764.
  • 3
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) Randomised Trial. HOT study group. Lancet. 1998;351:17551762.
  • 4
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: intervention as a Goal In Hypertension Treatment (INSIGHT). Lancet. 2000;356:366372.
  • 5
    Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359365.
  • 6
    Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with hypertension-2 study. Lancet. 1999;354:17511756.
  • 7
    Rosei EA, Dal Palu C, Leonetti G, et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS investigators. J Hypertens. 1997;15:13371344.
  • 8
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 9
    Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA. 2003;289:20732082.
  • 10
    Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, phase II, pilot and clinical trial. Circulation. 1991;83:448459.
  • 11
    Legault C, Furberg CD, Wagenknecht LE, et al. Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Stroke. 1996;27:593598.
  • 12
    Pahor M, Guralnik JM, Furberg CD, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 1996;347:10611065.
  • 13
    Kaplan RC, Heckbert SR, Koepsell TD, et al. Calcium channel blocker use and gastrointestinal tract bleeding among older adults. Age Ageing. 2002;31:217218.
  • 14
    Kaplan RC, Heckbert SR, Koepsell TD, et al. Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. Arch Intern Med. 2000;160:18491855.
  • 15
    Zuccala G, Pedone C, Cocchi A, et al. Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study. Gruppo Italiano di Farmacoepidemiologia nell'Anziano (GIFA) Investigators. Clin Pharmacol Ther. 2000;67:314322.
  • 16
    Zuccala G, Pahor M, Landi F, et al. Use of calcium antagonists and need for perioperative transfusion in older patients with hip fracture: observational study. BMJ. 1997;314:643644.
  • 17
    Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation. 2000;102:15031510.
  • 18
    Pales J, Palacios-Araus L, Lopez A, Gual A. Effects of dihydropyridines and inorganic calcium blockers on aggregation and on intracellular free calcium in platelets. Biochim Biophys Acta. 1991;1064:169174.
  • 19
    Wallen NH, Held C, Rehnqvist N, Hjemdahl P. Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. Am J Cardiol. 1995;75:16.
  • 20
    Blache D, Ojeda C. Comparative inhibitory effects of dihydropyridines on platelet aggregation, calcium uptake and cyclic AMP concentration. Pharmacology. 1992;45:250259.
  • 21
    Berkels R, Klaus W, Boller M, Rosen R. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process. Thromb Haemost. 1994;72:309312.
  • 22
    Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 2006;48:374384.
  • 23
    Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [design]. Am J Hypertens. 1996;9:342360.
  • 24
    Grimm RH Jr, Margolis KL, Papademetriou V, et al. Baseline characteristics of participants in the The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2001;37:1927.
  • 25
    Wright JT Jr, Cushman WC, Davis BR, et al. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. Control Clin Trials. 2001;22:659673.
  • 26
    Pressel S, Davis BR, Louis GT, et al. Participant recruitment in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Control Clin Trials. 2001;22:674686.
  • 27
    Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50:10961121.
  • 28
    The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial protocol. http://allhat.sph.uth.tmc.edu/Forms/protocol.pdf.
  • 29
    Centers for Disease Control and Prevention (CDC). International classification of diseases, ninth revision, clinical modification (ICD-9-CM). http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed May 9, 2012.
  • 30
    Kaplan RC, Heckbert SR, Koepsell TD, et al. Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study investigators. J Am Geriatr Soc. 2001;49:126133.
  • 31
    Suissa S, Bourgault C, Barkun A, et al. Antihypertensive drugs and the risk of gastrointestinal bleeding. Am J Med. 1998;105:230235.
  • 32
    Pilotto A, Leandro G, Franceschi M, et al. Antagonism to calcium antagonists. Lancet. 1996;347:17611762.
  • 33
    Lanas A, Serrano P, Bajador E, et al. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol. 2003;15:173178.
  • 34
    Kelly JP, Laszlo A, Kaufman DW, et al. Major upper gastrointestinal bleeding and the use of calcium channel blockers. Lancet. 1999;353:559.
  • 35
    Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:3339.
  • 36
    Smalley WE, Ray WA, Daugherty JR, Griffin MR. No association between calcium channel blocker use and confirmed bleeding peptic ulcer disease. Am J Epidemiol. 1998;148:350354.
  • 37
    Wijeysundera DN, Beattie WS, Rao V, et al. Calcium antagonists are associated with reduced mortality after cardiac surgery: a propensity analysis. J Thorac Cardiovasc Surg. 2004;127:755762.
  • 38
    Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology. 1997;25:6370.
  • 39
    Laine L. Upper gastrointestinal tract hemorrhage. West J Med. 1991;155:274279.
  • 40
    Fogari R, Preti P, Lazzari P, et al. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Eur J Clin Pharmacol. 2003;59:271275.
  • 41
    Sellin JH, Chang EB. Therapy insight: gastrointestinal complications of diabetes–pathophysiology and management. Nat Clin Pract Gastroenterol Hepatol. 2008;5:162171.
  • 42
    De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:22862294.
  • 43
    Al-Mallah M, Bazari RN, Jankowski M, Hudson MP. Predictors and outcomes associated with gastrointestinal bleeding in patients with acute coronary syndromes. J Thromb Thrombolysis. 2007;23:5155.
  • 44
    Thomsen RW, Riis A, Christensen S, et al. Diabetes and 30-day mortality from peptic ulcer bleeding and perforation: a Danish population-based cohort study. Diabetes Care. 2006;29:805810.
  • 45
    Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 2001;103:17461751.
  • 46
    Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation. 2002;105:457461.
  • 47
    Fogari R, Zoppi A, Malamani GD, et al. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol. 1995;39:471476.